TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02787044

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Trivalent Influenza Vaccine
Description: High Dose Trivalent Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Quadrivalent Influenza Vaccine
Description: Standard Dose Quadrivalent Influenza Vaccine
Study: NCT02135562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Material
Description: Receive carbohydrate reintroduction handout

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Education
Description: Receive education on nutrition label reading for carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight Maintenance
Description: weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Average score of Obesity and Weight-Loss Quality of Life Questionnaire
Description: Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
Study: NCT02247453

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening
Description: All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.~Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT.
Study: NCT02643264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rTMS 10 Hz targeting the insula
Description: Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation with the same regimen as active treatment
Study: NCT01012401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHESS website for lung cancer patient + internet access if needed
Description: The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHESS website for lung cancer patient + internet access if needed
Description: The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
Study: NCT04825405

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand motor coordination in a sitting position after use TipStim Glove
Description: The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: hand motor coordination in a sitting position after use TipStim Glove
Description: The next therapy with the use of Tip Stim took place after a week. The duration of each therapy session was 60 minutes. After the first therapy session and after a week, the parameters of movement coordination and handgrip were examined. The study of motor coordination and grip strength was performed in two different starting positions: sitting (no stabilization) and lying (with stabilization), and with a different position of the examined upper limb. The upper limb was examined in adduction, with the bent elbow joint in the intermediate position of the forearm. In each of the starting positions, first, the range of passive motion in the wrist joint (flexion and extension) and fingers (global flexion and extension) was measured, then the active movement was measured, in the sequence as above. Patients were asked to make movements as quickly and as fully as possible. Measurement of the grip force was performed after testing the ranges of motion and speed/frequency.
Study: NCT06147349

Intervention type: PROCEDURE
Intervention: Radical or partial nephrectomy
Description: Removal of neoplastic mass either by full kidney excision or by targeted cancer removal
Study: NCT04489810

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Maltodextrin capsule manufactured to mimic the Elevase® and DE111® capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elevase®
Description: 1 capsule containing 350 mg of Elevase®

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DE111®
Description: 1 capsule containing Bacillus subtilis DE111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal A
Description: Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal A
Description: Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meal A
Description: Oatmeal porridge - serving of cooked oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal B
Description: Refrigerated oatmeal - serving of refrigerated oats containing 50g of carbohydrates (excluding sugars); Wheat cereal - serving of wheat cereal providing 1g of gluten; Water - 125 mL
Study: NCT01786226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of mifepristone 2.5 mg daily for three months
Description: Experimental: 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral administration of mifepristone 5 mg daily for three months
Description: Experimental: 2
Study: NCT03845231

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flucelvax(R)
Description: Cohort 1 will receive IM quadrivalent IIV (Flucelvax (R)) at the standard dose of 15 micrograms HA per strain (60 micrograms HA total).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Challenge virus
Description: A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.

Intervention type: OTHER
Group type: OTHER
Intervention: Human Challenge virus
Description: A dose of 10\^7 50% tissue culture infective dose (TCID50) of human challenge virus will be administered intranasally to all participants using a nasal sprayer.
Study: NCT01572402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cous-cous sandwich
Description: 235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
Study: NCT01969682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
Study: NCT00531219

Intervention type: PROCEDURE
Intervention: Transgastric Appendectomy
Description: The appendix will be removed through an incision in the stomach and pulled out through the mouth

Intervention type: PROCEDURE
Intervention: Transgastric Cholecystectomy
Description: The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
Study: NCT01572402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cous-cous sandwich
Description: 235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: McCountry sandwich (McDonald's)
Description: 150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McCountry sandwich (McDonald's)
Description: 150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
Study: NCT00789360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo, 2 inhalations, 8 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Placebo
Description: Inhaled Staccato Placebo, 2 inhalations, 8 hours apart
Study: NCT00219947

Intervention type: OTHER
Intervention: blood draw
Description: * T cell subset enumeration~* Serologic reactivity with HIV antigens~* Viral load assays by bDNA, PCR, or RT-PCR~* Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)~* HIV-1 Resistance Testing
Study: NCT00789360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine
Description: Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine
Description: Inhaled Staccato Loxapine, 10 mg doses x 2, 8 hours apart
Study: NCT03139604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets administered orally once daily (QD) plus corticosteroids.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
Study: NCT03073252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Protein
Description: Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Protein
Description: Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIgh Protein
Description: Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIgh Protein
Description: Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
Study: NCT02206477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Sulfoxide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Study: NCT06237933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention via social networking site (SNS)
Description: We plan to organize a private Facebook group serve as platform to provide the intervention content. To ensure confidentiality, this Facebook group is completely private and the group member is invited only by study staff. The participants of intervention group received information about the private Facebook group and privacy settings and were instructed to join the Facebook group. The intervention comprises three parts. Doctor patient interaction: The interventionist (physicians and dietitians) act as health coach will provide evidence-based topics related to weight loss on Facebook discussion board every two weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: In the session, the participants are instructed by an interventionist to have a reduced calorie diet and regular physical activity. Calorie intake was prescribed based on baseline weight at 1200 kcal/d for individuals who weighed less than 90 kg, 1500 kcal/d for those who weighed 90 to less than 115 kg, and 1800 kcal/d for those who weighed 115kg or more. The interventionist will give each participants dietary recommendation and sample meal plans are provided to facilitate adoption. The interventionist will prescribe non-supervised moderate-to-vigorous physical activity to participants. Participants should start moderate-to-vigorous physical activity at 100 minutes per week and increased at 4-week intervals until a prescription of 300 minutes per week was achieved
Study: NCT00902070

Intervention type: DRUG
Intervention: Rocuronium
Description: Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
Study: NCT02417753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
Study: NCT01657162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate
Description: Alendronate is a bisphosphonate drug that prevents bone resorption by osteoclast and is used for the treatment of osteoporosis.
Study: NCT04625335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Massage Protocol
Description: Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.
Study: NCT02523703

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: glutamate and aspartate

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: glutamate and aspartate
Study: NCT02509832

Intervention type: DEVICE
Group type: OTHER
Intervention: Cooling + PCI
Description: Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
Study: NCT04625335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Massage Protocol
Description: Participants did not receive therapeutic massage prior to completing the Cold Pressor Test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic Therapeutic Massage
Description: Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic Therapeutic Massage
Description: Participants received a 5 minute prophylactic therapeutic massage prior to completing the Cold Pressor Test. The massage was completed distally-to-proximally in the following order: superficial strokes to the entire forearm, deep strokes to the entire forearm, one-handed palmar kneading of the entire forearm with participant's forearm stabilized by the massager's the other hand, bilateral thumb kneading of the forearm in strips until the entire forearm was addressed, bilateral transverse thumb motions over palmar surface of the hand, single thumb kneading of thenar and hypothenar eminences simultaneously, bilateral thumb kneading to the dorsum of hand, deep stroking to the entire forearm, and superficial stroking to the entire forearm.
Study: NCT00901342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
Study: NCT04238377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block
Description: Using US with a linear array transduce, subfascial-C6- Stellate Ganglion Block. Patients will be supine with the neck slightly hyper- extended. After aseptic preparation of the skin, the transducer is placed on the neck to enable cross sectional visualization of anatomical structures at the level of C6. The carotid artery, internal jugular vein, thyroid gland, trachea, longus colli covered with the prevertebral fascia, root of C6, and transverse process of C6 are all visualized. The transducer will then gently be pressed between the carotid artery and trachea to retract the carotid artery laterally and to position the transducer close to the longus colli.~A 1.0-inch, 25-gauge long-bevel needle were paratracheal inserted toward the middle of the longus colli. The endpoint for injection were the ultrasound image demonstrating the tip of needle penetrating the prevertebral fascia in the longus colli. After negative aspiration, 5 mL of 0.5% bupivacaine was injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal Analgesia
Description: Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal Analgesia
Description: Multimodal analgesia in the form of administering of IV paracetamol 1000 mg one hour prior to start of surgery in combination 30 mg ketorolac and Single preoperative 0.1 mg/kg dose dexamethasone has a combined action, anti-emetic and provides enhanced analgesia, with intra-operative fast acting opioid analgesics, Fentanyl 2 mic/kg
Study: NCT02245165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: saline
Study: NCT01559805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Choices
Description: A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Cognitive Counseling
Description: A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
Study: NCT01884948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omegaven™